Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MLN 3126

Next Previous
Drug Profile

MLN 3126

Alternative Names: MLN3126

Latest Information Update: 19 May 2015

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Takeda
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action CCR9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sjogren's syndrome

Most Recent Events

  • 19 May 2015 Discontinued - Phase-I for Sjogren's syndrome in USA (PO)
  • 17 May 2015 Takeda terminates a phase I trial in Healthy volunteers in USA (NCT02447458)
  • 01 Sep 2013 Takeda initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT02447458)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top